POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNalpha17 GENE

Abstract

The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFNα-17 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFNα-17 protein comprising at least one mutation caused by at least one SNP of the invention, as well as their therapeutic uses.

1 - 44 . (canceled) 
     
     
         45 . An isolated polynucleotide comprising a polynucleotide sequence having at least 95% identity to
 a) the polynucleotide sequence of SEQ. ID. NO.: 1,   b) the coding sequence of the polynucleotide sequence of SEQ. ID. NO.: 1; or   b) a polynucleotide sequence complementary to the polynucleotide sequence of a);
 wherein said sequences comprise at least one SNP g771c or SNP 808Ins(a). 
   
     
     
         46 . The polynucleotide of  claim 45 , wherein said polynucleotide sequence further comprises SNP g71c. 
     
     
         47 . The polynucleotide of  claim 45 , wherein said polynucleotide encodes an amino acid sequence having at least 95% identity with amino acids 24 to 189 of SEQ. ID. NO.: 2 and comprises SNP G45R. 
     
     
         48 . The polynucleotide of  claim 45 , wherein said polynucleotide encodes an amino acid sequence having at least 95% identity with SEQ. ID. NO.: 2 and comprises SNP G45R. 
     
     
         49 . The polynucleotide of  claim 45 , wherein the amino acid sequence encoded by said sequences exhibit antiviral, immunomodulatory, and/or antiproliferative activity. 
     
     
         50 . The polynucleotide of  claim 45 , wherein said polynucleotide encodes a IFNα-17 polypeptide comprising SNP G45R. 
     
     
         51 . The polynucleotide of  claim 45 , wherein said polynucleotide sequence consists of a polynucleotide sequence having at least 95% identity to
 a) the polynucleotide sequence of SEQ. ID. NO.: 1,   b) the coding sequence of the polynucleotide sequence of SEQ. ID. NO.: 1; or   b) a polynucleotide sequence complementary to the polynucleotide sequence of a);
 wherein said sequences comprise at least one SNP g771c or SNP 808Ins(a). 
   
     
     
         52 . The polynucleotide of  claim 45 , wherein said polynucleotide consists of the sequence of SEQ. ID. NO.: 1 and comprises SNP g771c. 
     
     
         53 . A recombinant vector comprising the polynucleotide of  claim 45 . 
     
     
         54 . A host cell comprising the recombinant vector of  claim 53 . 
     
     
         55 . An isolated polynucleotide consisting of a polynucleotide sequence encoding an amino acid sequence having at least 95% identity with SEQ. ID. NO.: 3. 
     
     
         56 . The polynucleotide of  claim 55 , wherein the polypeptide encoded by said polynucleotide comprises SNP G45R. 
     
     
         57 . A method for making a polypeptide having at least 95% identity with SEQ. ID. NO.: 2 and comprises SNP G45R comprising expressing the polynucleotide of  claim 45  in an appropriate cultivated host cell and isolating the expressed polypeptide from the culture of said host cell. 
     
     
         58 . A composition comprising the polynucleotide of  claim 45  and at least one pharmaceutically acceptable excipient. 
     
     
         59 . A composition comprising the vector of  claim 53  and at least one pharmaceutically acceptable excipient. 
     
     
         60 . A composition comprising the host cell of  claim 54  and at least one pharmaceutically acceptable excipient. 
     
     
         61 . A method for treating a disease comprising expressing the polynucleotide of  claim 45  in a patient in need thereof, wherein said disease is a cancer, tumor, or infectious disease. 
     
     
         62 . The method of  claim 61 , wherein said infectious disease is chronic hepatitis B, chronic hepatitis C, HIV/AIDS, infectious pneumonia, or a venereal disease.